Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term LUNG-CANCER. Found 14 abstracts

Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2014 Apr;32(12):1210-7.   PMCID: PMC3986384
Boquoi A, Jover R, Chen TN, Pennings M, Enders GH. Transgenic Expression of VEGF in Intestinal Epithelium Drives Mesenchymal Cell Interactions and Epithelial Neoplasia. Gastroenterology. 2009 Feb;136(2):596-606.   PMCID: PMC2824597
Ivanov SV, Miller J, Lucito R, Tang CL, Ivanova AV, Pei JM, Carbone M, Cruz C, Beck A, Webb C, Nonaka D, Testa JR, Pass HI. Genomic events associated with progression of pleural malignant mesothelioma. International journal of cancer. 2009 Feb;124(3):589-99.   PMCID: PMC2933144
Kim HJ, Barsevick AM, Tulman L. Predictors of the Intensity of Symptoms in a Cluster in Patients With Breast Cancer. Journal of Nursing Scholarship. 2009 Jan;41(2):158-65.   PMCID: PMC2884278
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. Cancer Research. 2009 Apr;69(7):3021-31.   PMCID: PMCID: PMC2871252
Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Association of k-ras mutational status and clinical outcomes in patients with metastatic colorectal. cancer receiving panitumumab alone. Clinical Colorectal Cancer. 2008 May;7(3):184-90.
Kim HJ, Barsevick AM, Tulman L, McDermott PA. Treatment-Related Symptom Clusters in Breast Cancer: A Secondary Analysis. Journal of Pain and Symptom Management. 2008 Nov;36(5):468-79.
Lioni M, Noma K, Snyder A, Klein-Szanto A, Diehl JA, Rustgi AK, Herlyn M, Smalley KS. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Molecular Cancer Therapeutics. 2008 Sep;7(9):2866-75.
Reinbold M, Luo JL, Nedelko T, Jerchow B, Murphy ME, Whibley C, Wei Q, Hollstein M. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene. 2008 Apr;27(19):2788-94.
Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM. Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. Journal of Immunotherapy. 2007 Sep;30(6):577-90.
Carter D, Vazquez M, Flieder DB, Brambilla E, Gazdar A, Noguchi M, Travis WD, Kramer A, Yip R, Yankelevitz DF, Henschke CI. Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening. Lung Cancer. 2007 May;56(2):193-9.
Chakravarti A, DeSilvio M, Zhang M, Grignon D, Rosenthal S, Asbell SO, Hanks G, Sandler HM, Khor LY, Pollack A, Shipley W. Prognostic value of p16 in locally advanced prostate cancer: A study based on radiation therapy oncology group protocol 9202. Journal of Clinical Oncology. 2007 Jul;25(21):3082-9.
Takaoka M, Kim SH, Okawa T, Michaylira CZ, Stairs DB, Johnstone CN, Andl CD, Rhoades B, Lee JJ, Klein-Szanto AJ, El-Deiry WS, Nakagawa H. IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biology & Therapy. 2007 Apr;6(4):534-40.
Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Current Cancer Drug Targets. 2006 Dec;6(8):691-710.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term LUNG-CANCER

LUNG-CANCER ENDOTHELIAL GROWTH-FACTOR EGFR EXPRESSION DIAGNOSIS THERAPY ANGIOGENESIS APOPTOSIS CARCINOMA FATIGUE ADJUVANT CHEMOTHERAPY WOMEN GENE-EXPRESSION TRANSVERSIONS INHIBITION PHASE-II MULTICENTER REGULATORY T-CELLS CT scan LOCALLY ADVANCED HEAD METASTATIC COLORECTAL-CANCER ADDUCTS SQUAMOUS-CELL CARCINOMA SOLID TUMORS monoclonal antibodies FACTOR-I RECEPTOR FETAL-HEMOGLOBIN LEVELS KAPPA-B lung cancer IGFBP-3 TYROSINE MECHANISM breast cancer PROTEASOME INHIBITOR BORTEZOMIB EPITHELIAL-CELLS MIN MICE head and neck squamous cell cancer screening CANCER CELLS RENAL-CELL CARCINOMA TYROSINE KINASE E2F PATHWAY MUTATIONAL ANALYSIS cetuximab antibodies GENERATION PERFORATION Symptom clusters PROTEIN-KINASE MICROARRAY ANALYSIS GASTROINTESTINAL PERFORATION ROLES FACTOR EXPRESSION GENE VASCULAR FUNCTION bronchioloalveolar carcinoma CETUXIMAB QUALITY-OF-LIFE ANGIOGENESIS INHIBITOR LYMPH-NODE METASTASES TRANSGENIC MICE PLUS NUMBER RECURRENT EPITHELIAL OVARIAN KRAS MUTATION IN-VITRO GENE-MUTATIONS RB GENE COPY NUMBER ACQUIRED-RESISTANCE HUMAN TUMOR XENOGRAFTS DRUG-RESISTANCE MELANOMA-CELLS breast neoplasm Symptom clusters-treatment-symptom management-symptom assessment-biological basis mesothelioma GROWTH-FACTOR-RECEPTOR CGH esophageal cancer SCATTER FACTOR ACTION PROJECT JUVENILE POLYPOSIS TGF-BETA SOMATIC MUTATIONS MURINE FIBROBLASTS TUMOR-GROWTH MULTIPLE-MYELOMA CELLS CROHNS-DISEASE POLYMORPHIC VARIANTS P53 Ras DENDRITIC CELLS BONE-MARROW oncogenes KERATINOCYTES N-CADHERIN monoclonal IGF HUMAN-CHROMOSOME 3P213 FACTOR RECEPTOR-1 tumor suppressors GROWTH FACTOR GROWTH-FACTOR RECEPTOR COPY NUMBER PROGNOSTIC-FACTORS treatment CELL METRONOMIC CHEMOTHERAPY BRAF DNA-DAMAGE Oncology COUNTY adenocarcinoma C-MET DISTRESS symptom management TUMOR PROGRESSION FACTOR-BINDING PROTEIN-3 ANAPLASTIC THYROID-CANCER POOR SURVIVAL DEPENDENT TUMORS PIK3CA FACTOR HOMOZYGOUS DELETION REGION BOWEL symptom assessment HOTSPOTS SMALL-MOLECULE INHIBITOR HOT-SPOTS ONCOSTATIN-M FACTOR-KAPPA-B ROMA copy number alterations TUMOR-SUPPRESSOR GENE pathology INHIBITOR PROGNOSTIC-SIGNIFICANCE TUMOR-SUPPRESSOR ARRAY-CGH DATA in vivo bioluminescence KINASE biologic effects targeted therapy ANDROGEN DEPRIVATION mutation hotspot lung cancer-embryonic broblasts-senescence-polymorphism radiation TUMOR ANGIOGENESIS SURVIVORS BEVACIZUMAB predictors
Last updated on Thursday, April 02, 2020